SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
5.00
+0.05 (1.01%)
Sep 11, 2026, 11:53 AM EDT - Market open
SciSparc Revenue
In the year 2025, SciSparc had annual revenue of $856.00K, down -34.46%. SciSparc had revenue of $856.00K in the quarter ending December 31, 2025, a decrease of -34.46%.
Revenue (ttm)
$856.00K
Revenue Growth
-34.46%
P/S Ratio
3.36
Revenue / Employee
$285,333
Employees
3
Market Cap
2.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 856.00K | -450.00K | -34.46% |
| Dec 31, 2024 | 1.31M | -1.57M | -54.64% |
| Dec 31, 2023 | 2.88M | 1.53M | 113.73% |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curis | 4.31M |
| 60 Degrees Pharmaceuticals | 1.21M |
| GeoVax Labs | 852.28K |
| Onconetix | 645.82K |
| BioRestorative Therapies | 357.87K |
| Jupiter Neurosciences | 64.69K |
| Silo Pharma | 54.08K |
SPRC News
- 8 days ago - SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire
- 9 days ago - SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire
- 10 days ago - SciSparc subsidiary provides update on SCI-210 trial enrollment - TheFly
- 10 days ago - SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - GlobeNewsWire
- 10 days ago - NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - TheNewswire
- 13 days ago - Neurothera Labs Inc. Announces Share Consolidation - TheNewswire
- 15 days ago - Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment - TheFly
- 15 days ago - NeuroThera Labs Engages Dr. Reuter Investor Relations - TheNewswire